• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV-1蛋白酶的二醇环脲抑制剂比其相应的醇形式结合得更紧密吗?一项通过自由能扰动和连续介质静电计算的研究。

Does a diol cyclic urea inhibitor of HIV-1 protease bind tighter than its corresponding alcohol form? A study by free energy perturbation and continuum electrostatics calculations.

作者信息

Wang L, Duan Y, Stouten P, De Lucca G V, Klabe R M, Kollman P A

机构信息

Department of Pharmaceutical Chemistry, University of California, San Francisco 94143-0446, USA.

出版信息

J Comput Aided Mol Des. 2001 Feb;15(2):145-56. doi: 10.1023/a:1008156222963.

DOI:10.1023/a:1008156222963
PMID:11272701
Abstract

The cyclic urea inhibitors of HIV-1 protease generally have two hydroxyl groups on the seven-membered ring. In this study, free energy perturbation and continuum electrostatic calculations were used to study the contributions of the two hydroxyl groups to the binding affinity and solubility of a cyclic urea inhibitor DMP323. The results indicated that the inhibitor with one hydroxyl group has better binding affinity and solubility than the inhibitor with two hydroxyl groups. Therefore, removal of one hydroxyl group from DMP323 may help to improve the properties of DMP323. This is also likely to be true for other cyclic urea inhibitors. The study also illustrated the difficulty in accurate modeling of the binding affinities of HIV-1 protease inhibitors, which involves many possible protonation states of the two catalytic aspartic acids in the active site of the enzyme.

摘要

HIV-1蛋白酶的环状尿素抑制剂通常在七元环上有两个羟基。在本研究中,采用自由能扰动和连续介质静电计算来研究这两个羟基对环状尿素抑制剂DMP323结合亲和力和溶解度的贡献。结果表明,含有一个羟基的抑制剂比含有两个羟基的抑制剂具有更好的结合亲和力和溶解度。因此,从DMP323中去除一个羟基可能有助于改善DMP323的性质。这对于其他环状尿素抑制剂可能也是如此。该研究还说明了准确模拟HIV-1蛋白酶抑制剂结合亲和力的困难,这涉及到酶活性位点中两个催化天冬氨酸的许多可能质子化状态。

相似文献

1
Does a diol cyclic urea inhibitor of HIV-1 protease bind tighter than its corresponding alcohol form? A study by free energy perturbation and continuum electrostatics calculations.HIV-1蛋白酶的二醇环脲抑制剂比其相应的醇形式结合得更紧密吗?一项通过自由能扰动和连续介质静电计算的研究。
J Comput Aided Mol Des. 2001 Feb;15(2):145-56. doi: 10.1023/a:1008156222963.
2
Interpreting trends in the binding of cyclic ureas to HIV-1 protease.解读环脲与HIV-1蛋白酶结合的趋势。
J Mol Biol. 2001 Jun 1;309(2):507-17. doi: 10.1006/jmbi.2001.4668.
3
Modified solvent accessibility free energy prediction analysis of cyclic urea inhibitors binding to the HIV-1 protease.环脲抑制剂与HIV-1蛋白酶结合的改良溶剂可及性自由能预测分析
Protein Eng. 2002 Sep;15(9):707-11. doi: 10.1093/protein/15.9.707.
4
Mapping hydration water molecules in the HIV-1 protease/DMP323 complex in solution by NMR spectroscopy.通过核磁共振光谱法对溶液中HIV-1蛋白酶/DMP323复合物中的水化水分子进行映射。
Biochemistry. 1996 Oct 1;35(39):12694-704. doi: 10.1021/bi9610764.
5
Stereoisomers of cyclic urea HIV-1 protease inhibitors: synthesis and binding affinities.环状尿素HIV-1蛋白酶抑制剂的立体异构体:合成与结合亲和力
J Med Chem. 1998 Dec 3;41(25):5113-7. doi: 10.1021/jm980255b.
6
Inhibitor docking screened by the modified SAFE_p scoring function: application to cyclic urea HIV-1 PR inhibitors.通过改良的SAFE_p评分函数筛选的抑制剂对接:应用于环脲HIV-1蛋白酶抑制剂
J Comput Chem. 2007 Oct;28(13):2216-25. doi: 10.1002/jcc.20741.
7
Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.HIV-1蛋白酶耐药性的分子基础:与环脲抑制剂复合的突变蛋白酶的结构分析
Biochemistry. 1997 Feb 18;36(7):1573-80. doi: 10.1021/bi962234u.
8
Three-dimensional solution structure of the HIV-1 protease complexed with DMP323, a novel cyclic urea-type inhibitor, determined by nuclear magnetic resonance spectroscopy.通过核磁共振光谱法测定的与新型环状脲类抑制剂DMP323复合的HIV-1蛋白酶的三维溶液结构。
Protein Sci. 1996 Mar;5(3):495-506. doi: 10.1002/pro.5560050311.
9
The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors.作为HIV蛋白酶抑制剂的对称和不对称P1/P1'环脲的合成。
Bioorg Med Chem Lett. 1998 May 5;8(9):1077-82. doi: 10.1016/s0960-894x(98)00175-9.
10
Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.作为HIV-1蛋白酶抑制剂的环脲衍生物的三维定量构效关系研究:比较分子场分析的应用
J Med Chem. 1999 Jan 28;42(2):249-59. doi: 10.1021/jm980369n.

引用本文的文献

1
Identification of HIV inhibitors guided by free energy perturbation calculations.基于自由能微扰计算的 HIV 抑制剂鉴定。
Curr Pharm Des. 2012;18(9):1199-216. doi: 10.2174/138161212799436421.
2
Correlation between the predicted and the observed biological activity of the symmetric and nonsymmetric cyclic urea derivatives used as HIV-1 protease inhibitors. A 3D-QSAR-CoMFA method for new antiviral drug design.用作HIV-1蛋白酶抑制剂的对称和非对称环脲衍生物的预测生物活性与观察到的生物活性之间的相关性。一种用于新型抗病毒药物设计的3D-QSAR-CoMFA方法。
J Cell Mol Med. 2003 Jul-Sep;7(3):287-96. doi: 10.1111/j.1582-4934.2003.tb00229.x.

本文引用的文献

1
Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7.应用于抗体48G7亲和力成熟的分子动力学和自由能计算。
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14330-5. doi: 10.1073/pnas.96.25.14330.
2
Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.HIV-1蛋白酶抑制剂:结构辅助药物设计的一项重大成就。
Annu Rev Biophys Biomol Struct. 1998;27:249-84. doi: 10.1146/annurev.biophys.27.1.249.
3
Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
HIV蛋白酶抑制剂的临床药理学:聚焦于沙奎那韦、茚地那韦和利托那韦。
Pharm World Sci. 1997 Aug;19(4):159-75. doi: 10.1023/a:1008629608556.
4
Experimental measurement of the effective dielectric in the hydrophobic core of a protein.蛋白质疏水核心中有效介电常数的实验测量。
Biophys Chem. 1997 Feb 28;64(1-3):211-24. doi: 10.1016/s0301-4622(96)02238-7.
5
Free energy perturbation studies on binding of A-74704 and its diester analog to HIV-1 protease.关于A-74704及其二酯类似物与HIV-1蛋白酶结合的自由能扰动研究。
Protein Eng. 1996 Sep;9(9):767-71. doi: 10.1093/protein/9.9.767.
6
Estimation of binding free energies for HIV proteinase inhibitors by molecular dynamics simulations.通过分子动力学模拟估算HIV蛋白酶抑制剂的结合自由能。
Protein Eng. 1995 Nov;8(11):1137-44. doi: 10.1093/protein/8.11.1137.
7
Free energy calculations of the mutation of Ile96-->Ala in barnase: contributions to the difference in stability.巴纳酶中异亮氨酸96突变为丙氨酸的自由能计算:对稳定性差异的贡献
Protein Eng. 1996 Mar;9(3):273-81. doi: 10.1093/protein/9.3.273.
8
A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.一种新型的、皮摩尔级的1型人类免疫缺陷病毒蛋白酶抑制剂。
J Med Chem. 1996 Jan 19;39(2):392-7. doi: 10.1021/jm9507183.
9
How does HIV cause AIDS?艾滋病病毒是如何引发艾滋病的?
Science. 1993 May 28;260(5112):1273-9. doi: 10.1126/science.8493571.
10
Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.强效、可生物利用的非肽环脲作为HIV蛋白酶抑制剂的合理设计。
Science. 1994 Jan 21;263(5145):380-4. doi: 10.1126/science.8278812.